|
In Vitro Assessment of Respiratory Hypersensitivity: Using Alternative Methods to Predict Respiratory Sensitization
|
Research Initiative
|
FDA
|
NIEHS
|
The primary goal of these efforts is to assess the utility of non-animal test methods for predicting human respiratory sensitization hazard in an expanded chemical space.
|
|
Incorporating Human Behavior in Epidemiological Models (IHBEM) Program
|
Research Initiative
|
Not Reported
|
NIDA
|
The IHBEM announcement is released under NSF-23-546. The purpose of the IHBEM activity is to support interdisciplinary collaborations that integrate research on behavioral and/or social processes in mathematical epidemiological models. Projects supported under this activity should be collaborative in nature and have coordinated interaction of two or more PIs/co-PIs, with balanced participation from the mathematical sciences and the social, behavioral, or economic sciences. Additional participants from other disciplines, especially the biological sciences, are also welcome.
|
|
Industrywide exposure assessment study of workers exposed to graphene and other two-dimensional nanomaterials
|
Research Initiative
|
CDC
|
NIEHS
|
There have been relatively few studies evaluating the toxicity of 2D nanomaterials and even fewer data are available regarding workplace exposures in the United States. This project will provide real-world exposure data along with important material characteristic information for the interpretation of current and future toxicity and risk assessment studies.
|
|
Infectious Diseases Clinical Research Program (IDCRP)
|
Research Initiative
|
Not Reported
|
NIAID
|
Interagency agreement between NIAID and the Uniformed Services University of the Health Sciences (USUHS) to develop and execute clinical research to address priority clinical concerns related to military-relevant infectious disease threats.
|
|
Influenza (Flu) Risk Management Meeting (FRMM) (aka HHS Pandemic and Seasonal Influenza Risk Management Meeting)
|
Committee, Work group, Advisory group, or Task Force
|
ASPR
|
NIAID
|
The Influenza (Flu) Risk Management Meeting (FRMM) is a senior-level forum for decision makers from stakeholder agencies to identify and address risk management issues related to the development, acquisition, deployment, and use of medical and public health countermeasures for influenza. Meetings provide members with a venue to discuss issues relating to the U.S. Department of Health and Human Services (HHS) response to pandemic influenza. Subjects for discussion include but are not limited to considerations of vaccine and antiviral stockpiles and clinical trial response to influenza outbreaks such as H7N9 and H3N2v. HHS Agency Collaborators on this activity include CDC, FDA, and OS.
|
|
Informal U.S. Government Nanoplastics Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, CDC, FDA
|
NIEHS
|
Formed in 2019 with the encouragement of the Nanoscale Science, Engineering, and Technology (NSET) Subcommittee of the National Science and Technology Council Staff support from the National Nanotechnology Coordination Office (NNCO). Purposes include:Share information, Enhance collaborations and coordinate research, Minimize redundancies, leverage resources and capabilities, Understand knowledge gaps. Thrust areas: Collection & Characterization , Hazard, Exposure, & Risk Assessment, Reduction & Mitigation.
|
|
Innovation Equity Forum (IEF) Women's Health R&D
|
Other
|
CDC, FDA
|
FIC, NCATS, NCI, NHLBI, NIA, NIBIB, NICHD, NIGMS, NIMH, NIMHD, NINDS, OD/DPCPSI/ODP, OD/DPCPSI/ORWH, OD/DPCPSI/SGMRO
|
The Innovation Equity Forum, convened by NIH and the Bill & Melinda Gates Foundation, consists of over 250 experts and community partners-representing over 50 countries and diverse perspectives in women's health. Forum members have developed an opportunity map to promote innovation that substantially impacts women's health within the next 15 years.
|
|
Innovation Equity Forum Steering Committee
|
Research Initiative
|
BARDA, FDA
|
FIC, NCATS, NCCIH, NHLBI, NIA, NICHD, NIGMS, NINDS, OD/DPCPSI/ORWH
|
Purpose:1.Convene a global community of key stakeholders and gatekeepers of health innovation around women’s health R&D (e.g., funders, researchers, and community partners) 2. Mobilize and accelerate innovations to improve women’s health through shared understanding of critical women’s health R&D priorities (where possible based on existing blueprints) 3. Foster cross-sector multinational partnerships to advance R&D efforts in women’s health innovation through enhanced coordination and collaboration
|
|
Inter-Agency Working Group for Bayh-Dole
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, CDC, FDA
|
OD/OER, OD/OSP
|
The Interagency Working Group for Bayh-Dole: Manages extramural research activities within the field of tech transfer and works to create consensus and policy across agencies, in consultation with the National Institutes of Health.
|
|
Inter-Agency Working Group on Technology Transfer
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NCI, NIAID, NIDA, NINDS, OD/OER, OD/OSP, OD/OTT
|
The Interagency Working Group for Technology Transfer: Identifies and disseminates creative approaches to technology transfer from Federal laboratories through an inter-agency task force.
|